How Can I Access Trientine in China if Penicillamine Makes Me Sick?

If penicillamine is causing intolerable side effects and you are living in China, you are facing a real and frustrating gap between what is available in other countries and what is approved where you are. Trientine (trientine dihydrochloride or trientine tetrahydrochloride) is the preferred alternative for patients who cannot tolerate penicillamine — it is well-established in North America and Europe — but as of 2025 it has not been registered by the National Medical Products Administration (NMPA) of China.¹ This page explains what your realistic options are, what the evidence says about why switching matters, and how to approach your doctor about the next step.

Why trientine matters if penicillamine is causing problems

Penicillamine is a copper chelator that has been used for Wilson disease since the 1960s. It works, but its side-effect profile is significant: early neurological worsening, autoimmune reactions, kidney damage, blood count changes, and skin problems occur in a meaningful proportion of patients.² Neurological worsening after starting penicillamine is particularly distressing — it affects roughly 10–50% of patients with neurological Wilson disease who begin the drug, and in a subset the worsening is not fully reversible.³

Trientine is also a copper chelator but with a different molecular structure and a substantially better tolerability profile. Multiple studies show that patients who could not tolerate penicillamine do well when switched to trientine, with effective copper mobilisation and fewer systemic side effects.⁴ It is now the first-line recommendation in the AASLD 2022 Practice Guidance and the EASL 2012 guidelines for patients intolerant to penicillamine, and increasingly is listed as an option from the start of treatment.⁵

Zinc is another alternative — it blocks copper absorption rather than chelating it — and is both available and affordable in China. It is discussed further below.

What is available inside China right now

Option	Availability in China	Notes
D-Penicillamine	Registered and widely available	First-line in most Chinese centres
Zinc acetate / zinc gluconate	Available, some brands registered	Suitable for maintenance or mild disease; lower copper-depleting effect than chelators
Trientine dihydrochloride (Syprine, Cuprior)	Not NMPA-registered	Legal import possible under specific conditions
Tetrathiomolybdate	Research phase globally; not approved anywhere	Not a current option

The personal import route

Chinese customs regulations permit individuals to import prescription drugs for personal use under certain conditions. In practice, this means:

1. A valid prescription from a licensed Chinese physician — your specialist at a hospital such as Beijing Tiantan Hospital (which has one of the country’s largest Wilson disease programmes) or the Anhui Medical University centre needs to be willing to prescribe trientine or support an application to use it.

2. Customs documentation — you or a family member bringing the drug in from abroad (typically from Hong Kong, the US, or Europe) must carry the prescription and ideally a letter from the treating hospital. Quantities are typically limited to a personal supply of three to six months.

3. No guarantee — customs officers have discretion, and there is no formal legal pathway specifically for trientine. Some patients succeed; others have their supply confiscated.

A 2021 study examining treatment persistence in Chinese Wilson disease patients found that drug availability, cost, and side-effect burden were the primary reasons patients discontinued therapy — underlining that this is a systemic problem, not an individual failing.⁶

The compassionate use pathway

China’s NMPA has a compassionate use (同情用药) programme for patients with serious diseases who have exhausted approved treatments. The formal pathway requires:

• Confirmation that approved treatments have failed or are contraindicated
• A hospital-level application (not an individual patient application)
• The drug manufacturer or distributor being willing to participate in a named-patient supply

In practice, trientine is not currently part of any named compassionate-use programme in China [unverified as of 2025]. However, your specialist at a major tertiary hospital is the right person to explore whether a hospital-level application is feasible. Academic medical centres sometimes have connections with pharmaceutical importers and international research networks that can facilitate access for individual patients.

Zinc as a bridge or long-term alternative

If importing trientine proves impossible in the short term, zinc supplementation (as zinc acetate or zinc sulfate) is a clinically meaningful option for patients who cannot tolerate penicillamine. Zinc works by blocking intestinal copper absorption — it is less powerful at removing copper quickly than trientine, but it is effective for maintenance and for patients with milder copper accumulation.⁷

The practical advantages in China: zinc preparations are widely available, inexpensive, and do not require any import process. The disadvantage is that zinc alone may be insufficient for patients with significant copper overload or active liver disease, where faster copper removal is needed. Your physician can guide whether zinc alone, or zinc while pursuing trientine access, is appropriate for your situation.

See medications-overview for a general comparison of Wilson disease treatment options, and what-to-tell-doctor for how to frame this conversation with your physician.

What to say to your specialist

When you see your doctor, consider asking directly:

• “I cannot tolerate penicillamine. Has the hospital ever arranged compassionate-use or named-patient access for trientine?”
• “Is zinc an appropriate short-term option while we explore alternatives?”
• “Is there a way to refer me to a research programme or clinical trial that might involve trientine?”
• “Can you write a letter supporting a personal import attempt?”

A specialist at a major Wilson disease centre — particularly one with international connections — is most likely to know what is feasible in the current regulatory environment. If you are not already at such a centre, a referral is worth pursuing.

Looking ahead

There is active global development of trientine formulations, and registration in Asian markets is being explored commercially. It is possible — though not guaranteed — that NMPA registration will occur within the coming years as the rare disease regulatory framework in China continues to evolve. Patients and families advocating through rare disease patient organisations can play a role in accelerating this process.

This information is for educational purposes only and is not legal or medical advice. Drug importation rules and compassionate-use policies change; please verify the current situation with your physician and, if needed, a legal adviser familiar with Chinese pharmaceutical regulations.

References